SpringerLink
Log in

Altered Drug Disposition Following Bariatric Surgery: A Research Challenge

  • Leading Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Bariatric surgery constitutes an approach to the management of obesity in which the anatomy of the gastrointestinal tract is altered to reduce access of nutrients to absorptive surfaces, to restrict the absolute volume of material that can be ingested at once, or a combination of the two. Roux-en-Y gastric bypass (RYGB), currently the most common bariatric surgical procedure worldwide, has both malabsorptive and restrictive features. RYGB can be associated with alterations in absorption and disposition of medications. However documenting and predicting the specific pharmacokinetic changes associated with RYGB is a difficult research challenge. Because obesity and weight loss themselves can alter drug disposition, it may be difficult or impossible to resolve whether pharmacokinetic alterations in post-RYGB patients are due to the surgery itself as opposed to the subsequent weight loss. Changes in disposition of medications may be drug-specific as opposed to generalized. Further, statistically significant modifications in drug disposition are not necessarily of clinical importance. Clinical decisions on medication use in post-bariatric surgical patients should be based on a review of the original literature dealing with the particular drug in question.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Greenblatt DJ. The seventy-kilogram fantasy. Clin Pharmacol Drug Dev. 2013;2:101–2.

    Article  Google Scholar 

  2. Darwich AS, Henderson K, Burgin A, et al. Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes. Br J Clin Pharmacol. 2012;74(5):774–87.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311(8):806–14.

    Article  CAS  PubMed  Google Scholar 

  4. Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obesity Surgery. 2013;23(4):427–36.

    Article  PubMed  Google Scholar 

  5. Buchwald H. The evolution of metabolic/bariatric surgery. Obes Surg. 2014;24(8):1126–35.

    Article  PubMed  Google Scholar 

  6. Arterburn DE, Courcoulas AP. Bariatric surgery for obesity and metabolic conditions in adults. BMJ. 2014;349:g3961.

    Article  PubMed  Google Scholar 

  7. Lo Menzo E, Szomstein S, Rosenthal RJ. Changing trends in bariatric surgery. Scand J Surg. 2015;104(1):18–23.

  8. Livingston EH. The incidence of bariatric surgery has plateaued in the US. Am J Surg. 2010;200(3):378–85.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Puzziferri N, Roshek TB, Mayo HG, Gallagher R, Belle SH, Livingston EH. Long-term follow-up after bariatric surgery: a systematic review. JAMA. 2014;312(9):934–42.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003–2012. JAMA Surg. 2014;149(3):275–87.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Abernethy DR, Greenblatt DJ. Pharmacokinetics of drugs in obesity. Clin Pharmacokinet. 1982;7:108–24.

    Article  CAS  PubMed  Google Scholar 

  12. Abernethy DR, Greenblatt DJ. Drug disposition in obese humans: an update. Clin Pharmacokinet. 1986;11:199–213.

    Article  CAS  PubMed  Google Scholar 

  13. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71–87.

    Article  CAS  PubMed  Google Scholar 

  14. Knibbe CA, Brill MJ, van Rongen A, Diepstraten J, van der Graaf PH, Danhof M. Drug disposition in obesity: toward evidence-based dosing. Annu Rev Pharmacol Toxicol. 2015;55:149–67.

    Article  CAS  PubMed  Google Scholar 

  15. Jain R, Chung SM, Jain L, et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther. 2011;90(1):77–89.

    Article  CAS  PubMed  Google Scholar 

  16. Morrish GA, Pai MP, Green B. The effects of obesity on drug pharmacokinetics in humans. Expert Opin Drug Metab Toxicol. 2011;7(6):697–706.

    Article  CAS  PubMed  Google Scholar 

  17. Cheymol G. Effects of obesity on pharmacokinetics: implications for drug therapy. Clin Pharmacokinet. 2000;39(3):215–31.

    Article  CAS  PubMed  Google Scholar 

  18. Greenblatt DJ, Koch-Weser J. Clinical pharmacokinetics. N Engl J Med. 1975;293:702–5, 964–70.

  19. Edwards A, Ensom MH. Pharmacokinetic effects of bariatric surgery. Ann Pharmacother. 2012;46(1):130–6.

    Article  CAS  PubMed  Google Scholar 

  20. Klockhoff H, Naslund I, Jones AW. Faster absorption of ethanol and higher peak concentration in women after gastric bypass surgery. Br J Clin Pharmacol. 2002;54(6):587–91.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Steffen KJ, Engel SG, Pollert GA, Li C, Mitchell JE. Blood alcohol concentrations rise rapidly and dramatically after Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2013;9(3):470–3.

    Article  PubMed  Google Scholar 

  22. Ertelt TW, Mitchell JE, Lancaster K, Crosby RD, Steffen KJ, Marino JM. Alcohol abuse and dependence before and after bariatric surgery: a review of the literature and report of a new data set. Surg Obes Relat Dis. 2008;4(5):647–50.

    Article  PubMed  Google Scholar 

  23. King WC, Chen JY, Mitchell JE, et al. Prevalence of alcohol use disorders before and after bariatric surgery. JAMA. 2012;307(23):2516–25.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Östlund MP, Backman O, Marsk R, et al. Increased admission for alcohol dependence after gastric bypass surgery compared with restrictive bariatric surgery. JAMA Surg. 2013;148(4):374–7.

    Article  PubMed  Google Scholar 

  25. Greenblatt DJ, Abernethy DR, Divoll M. Is volume of distribution at steady-state a meaningful kinetic variable? J Clin Pharmacol. 1983;23:391–400.

    Article  CAS  PubMed  Google Scholar 

  26. Greenblatt DJ. Volume of distribution—again. Clin Pharmacol Drug Dev. 2014;3:419–20.

    Article  Google Scholar 

  27. Abernethy DR, Greenblatt DJ, Divoll M, Harmatz JS, Shader RI. Alterations in drug distribution and clearance due to obesity. J Pharmacol Exp Ther. 1981;217:681–5.

    CAS  PubMed  Google Scholar 

  28. Gandhi A, Moorthy B, Ghose R. Drug disposition in pathophysiological conditions. Curr Drug Metab. 2012;13(9):1327–44.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Dostalek M, Akhlaghi F, Puzanovova M. Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs. Clin Pharmacokinet. 2012;51(8):481–99.

    Article  CAS  PubMed  Google Scholar 

  30. Yska JP, van der Linde S, Tapper VV, et al. Influence of bariatric surgery on the use and pharmacokinetics of some major drug classes. Obes Surg. 2013;23(6):819–25.

    Article  PubMed  Google Scholar 

  31. Matheson PJ, Hurt RT, Franklin GA, McClain CJ, Garrison RN. Obesity-induced hepatic hypoperfusion primes for hepatic dysfunction after resuscitated hemorrhagic shock. Surgery. 2009;146(4):739–47.

    Article  PubMed  Google Scholar 

  32. Subramanian M, Kurawattimath V, Pocha K, et al. Role of hepatic blood flow and metabolism in the pharmacokinetics of ten drugs in lean, aged and obese rats. Xenobiotica. 2014;44(12):1108–16.

    Article  CAS  PubMed  Google Scholar 

  33. Xu J, Kulkarni SR, Li L, Slitt AL. UDP-glucuronosyltransferase expression in mouse liver is increased in obesity- and fasting-induced steatosis. Drug Metab Dispos. 2012;40(2):259–66.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Abernethy DR, Divoll M, Greenblatt DJ, Ameer B. Obesity, sex, and acetaminophen disposition. Clin Pharmacol Ther. 1982;31(6):783–90.

    Article  CAS  PubMed  Google Scholar 

  35. Abernethy DR, Greenblatt DJ, Divoll M, Shader RI. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. J Lab Clin Med. 1983;101(6):873–80.

    CAS  PubMed  Google Scholar 

  36. Miller AD, Smith KM. Medication and nutrient administration considerations after bariatric surgery. Am J Health Syst Pharm. 2006;63(19):1852–7.

    Article  PubMed  Google Scholar 

  37. Smith A, Henriksen B, Cohen A. Pharmacokinetic considerations in Roux-en-Y gastric bypass patients. Am J Health Syst Pharm. 2011;68(23):2241–7.

    Article  CAS  PubMed  Google Scholar 

  38. Brocks DR, Ben-Eltriki M, Gabr RQ, Padwal RS. The effects of gastric bypass surgery on drug absorption and pharmacokinetics. Expert Opin Drug Metab Toxicol. 2012;8(12):1505–19.

    Article  CAS  PubMed  Google Scholar 

  39. De Smet J, Van Bocxlaer J, Boussery K. The influence of bypass procedures and other anatomical changes in the gastrointestinal tract on the oral bioavailability of drugs. J Clin Pharmacol. 2013;53(4):361–76.

    Article  PubMed  Google Scholar 

  40. Titus R, Kastenmeier A, Otterson MF. Consequences of gastrointestinal surgery on drug absorption. Nutr Clin Pract. 2013;28(4):429–36.

    Article  PubMed  Google Scholar 

  41. Stein J, Stier C, Raab H, Weiner R. Review article: the nutritional and pharmacological consequences of obesity surgery. Aliment Pharmacol Ther. 2014;40(6):582–609.

    Article  CAS  PubMed  Google Scholar 

  42. Tandra S, Chalasani N, Jones DR, Mattar S, Hall SD, Vuppalanchi R. Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. Ann Surg. 2013;258(2):262–9.

    Article  PubMed  Google Scholar 

  43. Padwal RS, Gabr RQ, Sharma AM, et al. Effect of gastric bypass surgery on the absorption and bioavailability of metformin. Diabetes Care. 2011;34(6):1295–300.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  44. Rogers CC, Alloway RR, Alexander JW, Cardi M, Trofe J, Vinks AA. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. Clin Transplant. 2008;22(3):281–91.

    Article  PubMed Central  PubMed  Google Scholar 

  45. Lloret-Linares C, Hirt D, Bardin C, et al. Effect of a Roux-en-Y gastric bypass on the pharmacokinetics of oral morphine using a population approach. Clin Pharmacokinet. 2014;53(10):919–30.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors have no conflicts of interest. There was no source of funding for the preparation of this article.

Author information

Authors and Affiliations

  1. Program in Pharmacology and Experimental Therapeutics, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA, 02111, USA

    H. Karl Greenblatt & David J. Greenblatt

Authors
  1. H. Karl Greenblatt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David J. Greenblatt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David J. Greenblatt.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Greenblatt, H.K., Greenblatt, D.J. Altered Drug Disposition Following Bariatric Surgery: A Research Challenge. Clin Pharmacokinet 54, 573–579 (2015). https://doi.org/10.1007/s40262-015-0259-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-015-0259-1

Keywords

Search

Navigation